PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Ocimum Biosolutions, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ocimum Biosolutions Launches the Software as a Service Version of its Biotracker™ Biobanking LIMS - Ocimum Biosolutions, announced that it has launched Biotracker™ for Biobanking SaaS, the Software as a Service version of its LIMS for biorepositories
Ocimum Biosolutions Launches the Software as a Service Version of its Biotracker™ Biobanking LIMS

 

NewswireToday - /newswire/ - Hyderabad, Andhra Pradesh, India, 2010/06/24 - Ocimum Biosolutions, announced that it has launched Biotracker™ for Biobanking SaaS, the Software as a Service version of its LIMS for biorepositories.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Ocimum Biosolutions, a leading provider of Life Sciences Laboratory Information Management Systems (LIMS) and genomic solutions, is pleased to announce that it has launched Biotracker™ for Biobanking SaaS, the Software as a Service version of its LIMS for biorepositories.

Biotracker™ Biobanking is a fully scalable, configurable, customizable, complete biobanking solution. Now that Biotracker™ Biobanking is available as a Software as a Service (SaaS), biobanks will be able to utilize the system over the internet without the need for increasing their IT infrastructure or workload.

“Having run and managed biobanks for both our own labs and for a variety of customers for many years, Ocimum Biosolutions has demonstrable working expertise in this domain”, stated Anu Acharya, CEO of Ocimum Biosolutions. “We leveraged our biobanking domain expertise when designing our Biotracker™ Biobanking solution and now we have leveraged our IT expertise to make Biotracker™ Biobanking available as a hosted service over the internet. This is a part of our ongoing efforts to bring RaaS (Research as a Service) to our partners”, continued Ms. Acharya.

Biotracker™ Biobanking has specialized features that include a Requester Module, Donor/Patient and Biospecimen Management with full Genealogy, Unlimited Meta Data Annotation, Controlled Vocabulary and Synonyms, Data and Location Management, TMA, CMA, and much more. Biotracker™ Biobanking is caBIG® Bronze Certified, providing the highest degree of integratability and interoperability while also supporting Regulatory Compliancy (HIPAA, 21CFR11, GxP, CLIA, etc.)

About Biotracker™ Biobanking SaaS
Biotracker™ Biobanking SaaS offers an easy, "pay-as-you-go" solution for all current and long-term biobanking needs. Biotracker™ Biobanking SaaS now offers the benefit of a full featured Biobanking LIMS over the Internet to small and medium biobanking labs which previously would only be available within large enterprises. The intuitive user interface, ease-of-use and online access makes the adoption for use rate for Biotracker™ Biobanking SaaS very high by the lab personnel while simultaneously creating a better user experience. This greatly increases the likelihood of full utilization of all the system features yielding maximum value for a minimal investment.

About Ocimum Biosolutions

Ocimum Biosolutions (ocimumbio.com) is an integrated global genomic services company with operations in Hyderabad, India and Gaithersburg, MD. We provide comprehensive (research level and GLP-compliant) genomic services, reference databases, and LIMS solutions. Our distinct platform "Research as a Service" (RaaS) allows complete outsourcing of genomics – from storing biological samples and performing on demand DNA and RNA based services to validating biomarkers using our proprietary databases and providing data and bioinformatic analysis. We have been chosen as a global preferred outsourcing provider for more than 75% of top 25 pharma and biotech companies plus leading research institutes. Our partners recognize our expertise for understanding disease mechanisms in correlation with discovery, prioritization of gene targets and biomarkers, and sample analysis for clinical studies.

With our global infrastructure’s standardized procedures, capacity, and highly skilled staff, we are capable of supporting drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. Our expertise is unparalleled and was gained through the creation of the world’s largest commercial gene expression databases – BioExpress® and ToxExpress®. Ocimum has been consistently ranked as India’s fastest growing biotechnology company and one of the fastest growing technology companies over the last five years by Deloitte Touche Tohmatsu.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Ocimum Biosolutions, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Ocimum Biosolutions Launches the Software as a Service Version of its Biotracker™ Biobanking LIMS

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: OcimumBio.com 
+91 40 66986700 row[.]ocimumbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Ocimum Biosolutions, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Ocimum Biosolutions, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)